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ABSTRACT 
Currently there is a global trend to eliminate the use of antibiotic growth promoters 
(AGP) in animal production due to the risk of creating reservoirs of antibiotic resistant bacteria.  
Previous studies have shown that the ability of AGP to promote growth is highly correlated with 
a decrease in the activity of bile salt hydrolase (BSH), an enzyme produced by commensal 
bacteria and whose actions may compromise host lipid metabolism; thus, BSH inhibitors could 
be a novel AGP alternative.  In this study, a recombinant bile salt hydrolase (rBSH) from 
Lactobacillus salivarius was produced in an E. coli expression system, purified, and 
enzymatically characterized.  Purification by nickel-nitrilotriacetic acid (Ni-NTA) affinity 
chromatography consistently yielded approximately 15 mg of rBSH per liter of induced culture.   
A standard 2-step BSH activity assay which estimates the amount of amino acids liberated from 
conjugated bile acids was used to determine substrate specificity of the BSH and the effect of 
pH, temperature, and dietary compounds on BSH activity.  The rBSH displayed its highest 
hydrolysis activity for glycochenodeoxycholic acid although there was no preference among 
other substrates tested.   Optimal activity was observed between pH of 5.0 and 6.0 and between 
temperatures of 35°C to 55°C.  Preliminary assays identified different dietary compounds that 
were potent inhibitors, including copper and zinc compounds which have previously been shown 
to boost feed efficiency and promote growth of poultry and swine.  Furthermore, a high-
throughput screening system (HTS) was developed for fast and efficient identification of potent 
BSH inhibitors.   This HTS system was utilized to screen a compound library comprised of 2,240 
biologically active and structurally diverse compounds.  The pilot screen led to 107 hits and a 
preliminary review of biochemical information of the corresponding compounds further 
narrowed down those of interest.  Several lead compounds have been validated by the standard 
2-step BSH activity assay and will be subjected to future in vivo analysis in a large-scale animal 
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study.  Overall, this study characterized a BSH with broad substrate specificity and developed 
and validated different strategies for identification of BSH inhibitors, the promising alternatives 
to AGP for enhancing the productivity and sustainability of food animals.       
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CHAPTER I 
LITERATURE REVIEW 
 
Antibiotic growth promoters:  history and mode of action 
The animal production industry is one that measures success in terms of quality.  In order 
to maximize efficiency, a balance must exist between growth and health.  One of the primary 
means that producers seek to ensure such quality in food animals is via antibiotic growth 
promoters (AGP).  Antibiotic growth promoters are subtherapeutic quantities of antibiotics, such 
as tetracycline or bacitracin, that are added to animal feed for enhancement of growth and feed 
conversion ratio (Marshall & Levy 2011).  Unlike antibiotics that are used for therapeutic 
treatment for sick animals or prophylactically for infection prevention, AGP are aimed at 
enriching feed utilization and early indications of improvement of production efficiency occurred 
as early as 1946 (Moore et al.).  However, AGP generally started being promoted in the mid-
1950s after it was found that they could improve the feed-to-weight ratio in poultry, swine, and 
beef cattle (Stokestad & Jukes 1950).  Since then, AGP have been widely used in the United 
States and elsewhere in agriculture as a means of propagating healthy and robust food animals.  
Other ancillary values of AGP may include environmental gains because of less nitrogen and 
phosphorous excretion, improved animal welfare, and even enhanced milk, wool, and egg 
production as well as fertility (Barton 2000).  Equally important, from an economic standpoint, 
AGP are attractive to producers because they can improve financial gains due to improved feed 
efficiency and reduced morbidity and mortality.  Recent estimates are difficult to gauge; 
however, a1999 book compiled by the Committee on Drug use in Food Animals et al. states that 
during some period of their lives nearly 100% of poultry, 90% of swine and veal calves, and 
60% of beef cattle are fed diets incorporating AGP (Animals, Panel on Animal Health et al. 
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1999), so clearly producers rely on these products to benefit their production systems.  Based on 
the wide-ranging effects that AGP confer to both animals and farmers, recent suggestions to curb 
their usage (as will be later discussed) are undoubtedly a cause for great concern among 
producers and consumers alike.  
Although precise mechanisms have yet to be elucidated, it is widely accepted that AGP 
achieve growth promoting effects because of their interactions with intestinal microflora.  This is 
supported by the fact that oral antibiotics fail to produce any growth promoting effects in germ 
free animals (Coates et al. 1963), and in fact, AGP tend to create intestinal conditions which 
approach those of germ free animals (Commission on Antimicrobial Feed Additives 1997).  The 
gastrointestinal (GI) tract of vertebrate animals is rife with diverse microflora, much of which is 
gram-positive bacteria, and as such are extremely influential to GI physiology, immunity, and 
nutrition (Dibner & Richards 2005).  Although commensal bacteria perform critical roles in 
nutrition and development, advantages may be countered by certain detrimental effects to the 
host.  Microflora provide benefits in the form of nutrients through the production and secretion 
of volatile fatty acids and vitamins, competitively exclude pathogenic bacteria from colonization, 
and are important in stimulating host intestinal immune defenses (Dibner & Richards 2005).  
Negative impacts are the result of competition for nutrients, secretion of toxic compounds, and 
undesired immunological responses in the GI tract (Gaskins et al. 2002).  Antibiotics, therefore, 
are important modulators of gut microflora and are implicated to improve host interactions with 
normal microflora by limiting nutrient competition and reducing harmful secondary metabolites 
that may weaken growth (Dibner & Richards 2005).   
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AGP and antibiotic resistance in zoonotic pathogens 
Any use of antibiotics, whether it is for therapeutic or subtherapeutic purposes, will 
create selection pressures for drug resistant bacteria.  Particularly as is the case for AGP, the 
large number of animals that receive a low-dosage of antibiotic in combination with a steady and 
prolonged delivery into the feed system generates selection pressure for emergence, persistence, 
and transmission of antibiotic resistant bacteria (Marshall & Levy 2011). If and when these 
resistant bacteria proliferate, modes of transmission from animal to humans can occur through 
direct contact with the colonized or infected animal or indirectly through the food chain (van den 
Bogaard & Stobberingh 1999).  The major concerns regarding animal derived antibiotic resistant 
zoonotic pathogens are aimed at enteric bacteria like E. coli, Salmonella, Campylobacter, and 
Enterococcus.  All could be commensals of food animals but have the potential to become 
dangerous human pathogens and evidence exists for isolates of antibiotic resistant pathogens 
after AGP treatment.  Not long after AGP became common additives to feed, tetracycline 
resistant E. coli isolates were detected from chickens and pigs (Smith 1967); soon after, 
antibiotic resistant Salmonella was reported (Anderson 1968).  Emerging multi-drug resistant 
Salmonella in the 1960s prompted the establishment of the Swann Committee to address the 
concerns of transferable animal derived human pathogens.  Their report recommended that AGP 
in a class also used for human therapy should be discontinued to prohibit drug-resistant 
infections (Swann 1969), yet these practices continued in the U.S. and Europe.  Both E. coli and 
Salmonella resistance is a continuing phenomenon (Folster et al. 2012; Ramos et al. 2012), and 
in the 1990s different concerns arose when Campylobacter isolates of poultry and swine were 
found to be resistant to erythromycin, ampicillin, streptomycin, and ciprofloxacin, among others 
(Lucey et al. 2000; Moore et al. 1996; Saenz et al. 2000).  In 1995 the Danish Veterinary 
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Laboratory documented vancomycin-resistant Enterococcus faecium in pigs and poultry 
receiving avoparcin laced feed (Barton 2000); Aarestrup et al. (1999) later found a high 
prevalence for E. faecium resistance to tylosin and virginiamycin in Norwegian swine and 
poultry.  Additionally, methicillin resistant Staphylococcus aureus (MRSA) colonization in food 
animals and their farmers has been implicated as a reservoir of animal derived MRSA that could 
contribute to human infection and for community acquired MRSA infections as a result of 
contaminated meat consumption (Khanna et al. 2008; Ogata et al. 2012; Oppliger et al. 2012). 
The last few decades have unveiled selective pressures of AGP on commensal and 
pathogenic flora of food animals (Akwar et al. 2007; Bager et al. 1997; Hummel et al. 1986; 
Levy 1976) and knowing that they can easily cross the human barrier is a formidable realization. 
A 2011 review published in Clinical Microbiology by Marshall and Levy lists crucial evidence 
of just such resistance transfer and it cites multiple studies confirming human colonization and 
infection of animal derived resistant bacteria.  Furthermore, estimates of AGP excretion back 
into the environment range from 75-90% (Costa et al. 2010; Kumar et al. 2005), constituting 
exposure of innumerable environmental bacteria to minute doses of antibiotics and generating 
the potential for widespread resistance selection, which may be further complicated by horizontal 
gene transfer as a means of resistance transmission.  Clearly, efforts need to be made to curtail 
this phenomenon, and discontinuing the use of AGP is likely a good means of doing so. 
 
The current status of AGP 
Because of the looming threat that using antibiotics as growth promoters in animals has 
aroused valid suspicion that human health could negatively be impacted, efforts have been made 
to generate awareness about the potentially dangerous practice as well as to limit and terminate 
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altogether the use of AGP.  The previously mentioned Swann Report resulted in changes in 
England, Canada, and some European countries, but failed to make an impact elsewhere.  Other 
councils and committees have drafted similar guidelines as to how AGP usage should be 
monitored or curtailed for preservation of public health, including  the Institute of Medicine, the 
Council for Agricultural Science and Technology, the Committee on Drug Use in Food Animals, 
and the Poultry Science Association (Dibner & Richards 2005); the World Health Organization 
(WHO) has also published several reports regarding antimicrobial usage in food animals in an 
ongoing effort to reduce their need in agriculture and aquaculture (WHO 1997; 2000; 2004; 
2006).  Leaders in the front to revolutionize safety practices in animal production, European 
Union (EU) countries were among the first to implement restrictive policies and create a standard 
by which agricultural practices may be modeled throughout other areas of the world.  Sweden 
was the first to ban AGP in 1986, followed by a ban on avoparcin in Denmark in 1995 and in 
1997 by all EU member states; Denmark further banned all AGP for swine at the weaning and 
finishing levels on January 1, 2001 (Dibner & Richards 2005).  Following bans on individual 
AGP in 1998 and 1999, the EU later banned all others as of January 1, 2006.    
With increased concern from public health officials, it is likely that the trend of phasing 
out or eliminating AGP will continue in the United States and elsewhere.  In 2000, the World 
Health Organization issued a report urging the need for national governments to “adopt a 
proactive approach to reduce the need for antimicrobials in animals and their contribution to 
antimicrobial resistance and to ensure their prudent use (including reducing overuse and misuse), 
as elements of a national strategy for the containment of antimicrobial resistance” (WHO 2000).   
The report further suggested that food producers voluntarily, but by legislation if necessary, 
terminate or speedily phase out AGP that are in a class used by humans and avoid the 
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prophylactic use of antimicrobials in animal management.  In 2010, the FDA issued a draft 
guidance in support of phasing out antimicrobials in food animals to reduce selection pressures 
and protect public health (Sharfstein 2010). This was followed by a court ruling in March of 
2012 that the FDA should begin retracting the allowance for the use of certain antibiotics used 
for production purposes in food animals except under veterinary supervision (Veterinary Record 
2012).  Clearly the impetus exists to discontinue using AGP, and sooner or later their removal 
will be dictated by both public demand and economic pressures to maintain export markets with 
countries that have already banned AGP as an agricultural practice.  While eliminating AGP is a 
good idea to prevent widespread resistance, it is clear that alternative strategies must be 
implemented to guarantee that animal health and nutrition are not compromised and to offset 
economic setbacks for animal producers. 
Although eliminating AGP usage is a noble goal, there is obvious concern over the 
potentially negative consequences that may ensue from so suddenly ceasing to include these 
subtherapeutic antibiotics in animal feed.  Shortly after the early EU AGP ban there was a 
consequent rise in the use of therapeutic antibiotics to treat infection, generating alarm because 
they were those also used in human medicine (Casewell et al. 2003).  Likewise, after Denmark’s 
2001 ban of AGP there was an increase in tetracycline and sulphonamide resistance in S. 
typhimurium in both pigs and humans and more Campylobacter resistance to tetracycline and 
fluoroquinolones in humans than in animals (DANMAP 2001).  Animal welfare also seemed to 
suffer immediately following Denmark’s ban:  increased reports of morbidity and mortality were 
identified in pigs and attributed largely to enteric infections (Casewell et al. 2003) and clostridial 
necrotic enteritis emerged as well (Tornee 2002).  These immediate pitfalls were somewhat 
expected, but what enduring effects does AGP banning really introduce?  
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Denmark’s early ban of AGP even before the comprehensive ban in the entire EU 
presents us with a unique opportunity to gauge how large-scale bans in other countries may play 
out.   One of the most comprehensive studies was conducted by Aarestrup et al. (2010) and 
examined production, disease, and antibiotic use on swine farms from 1992 to 2008.  As to 
overall antimicrobial consumption per animal, there was a decrease by over 50% and long-term 
productivity actually improved despite an initial increase in diarrhea in weaning pigs and a 
consequent increase in therapeutic antibiotics.  A 2002 executive summary published by WHO 
also mentioned loss in productivity in weaner pigs and decreased feed efficiency in poultry 
production, but noted that in Denmark the termination of AGP led to a drastically reduced food 
animal pool of resistant enterococci and concluded that necrotic enteritis in broilers was only a 
minor problem since ionophores were still implemented for prophylaxis of coccidiosis.  The 
WHO further determined that discontinuing AGP is largely beneficial in reducing the total 
amount of antimicrobials given to food animals and consequently reducing antimicrobial 
resistance that threatens both animal and human health. Additionally, they estimate that 
economic impacts are relatively minor and in some cases offset by cost savings associated with 
not having to buy AGP, although they suggest that costs may have been substantial for some 
producers.   
Though the consensus in Denmark seems to favor the ban on AGP, Sweden has 
experienced more problems.  Sixteen years after their 1986 ban of AGP, the loss in swine 
production had not been fully recovered (Casewell et al. 2003) and total antimicrobial 
consumption was at the same level as before the ban (Aarestrup et al. 2010).  Considering this 
and the early difficulties experienced in Denmark, results seem mixed as to whether the ban is 
largely beneficial to animal production or compromising of animal welfare.  Therefore, how the 
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United States would respond to a total ban of AGP is unclear since antimicrobial consumption 
here is much higher than the EU mean value (Aarestrup et al. 2010).  Moving away from a 
reliance on AGP in animal production is in our best interest and may even benefit production 
long-term, but due to initial compromises in animal health, it would still be beneficial to institute 
alternatives to AGP that facilitate growth enhancement in their absence.  It is fair to assume that, 
at least initially, safe AGP alternatives would be a logical first step in the transition.   
 
Response of the intestinal microbiota to AGP 
 In order to implement alternatives, we must reexamine the mechanism of action of AGP.  
As previously discussed, it is proposed that AGP promote growth because of their effects on the 
GI microflora.  Specifically, the small intestine is a prime target of effect because 1) it is where 
most nutrients are absorbed and 2) here there is a high density of bacterial numbers (Rettedal et 
al. 2009).  Studies performed on swine and poultry to demonstrate the effects of antibiotics on 
intestinal microflora note interesting bacterial shifts (Collier et al. 2003; Dumonceaux et al. 
2006; Rettedal et al. 2009).  What seems to happen is that the abundance of some bacterial 
species increase in numbers while others decrease, and particularly Lactobacilli are affected.  
Collier et al. (2003) found that antibiotic rotations selected against three Lactobacilli, one 
Bacillus, and one Streptococcus species in pig ileal microbiota, while treatment with tylosin 
alone tended to increase lactobacilli concentration as a percentage of total bacteria here.  Also 
observed was an antibiotic-induced homogenization of the ileal microbiota, which could explain 
uniform growth enhancement seen in animals given AGP.  Similarly, Retedal et al. (2009) 
reported that inclusion of chlortetracycline in the diet influenced porcine ileal bacteria in such a 
way as to decrease the abundance of L. johnsonii and increase that of L. amylovorus.  Regarding 
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poultry, the observation has been made that dietary AGP improved weight gain and feed 
conversion ratios while diminishing ileal L. salivarius populations, indicating their potential 
detrimental effect on poultry nutrition (Dumonceaux et al. 2006; Guban et al. 2006).  By 
focusing on these small intestine microbes that are heavily influenced by AGP, beneficial 
commensals may be noted, but more importantly the opportunity arises to understand why 
certain species are deleterious to animal growth.  
 
Response of intestinal bile salt hydrolase activity to AGP 
Clearly a connection has been made between AGP, growth promotion, and intestinal 
bacterial populations, but the precise mechanism is yet to be delineated as to how these all 
coincide.   Strides have been made in uncovering this mystery, however, and it has been shown 
that the growth promoting effect of low-dose antibiotics does coincide with a decrease in bile salt 
hydrolase activity (BSH) in the gut (Feighner & Dashkevicz 1987; Guban et al. 2006; 
Hunkapillar et al. 2009; Knarreborg et al. 2004).  BSH is an enzyme produced by commensal 
bacteria in the host’s intestine whose main function is to transform conjugated bile salts into 
unconjugated bile salts.  Bile salts (also referred to as bile acids) are one of several components 
of bile and their amphipathic nature, which is facilitated by amino acid conjugation with glycine 
or taurine, significantly contributes to the emulsification of dietary lipids and micelle formation.  
BSH liberates this glycine or taurine moiety by hydrolysis of the amide bond and transforms a 
conjugated bile salt that is effective at solubilizing lipids into a deconjugated bile salt that is 
inefficient in lipid emulsification and undesirable for lipid digestion and absorption.  Because 
this results in altered lipid metabolism and micelle formation, normal host digestive functions 
may be impaired.  Indeed, because unconjugated bile acids are less water soluble, they are 
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readily excreted in the feces.  The potential for BSH producing bacteria to lower serum 
cholesterol by reducing its solubility and increasing the amount of free bile acids lost in the feces 
is debatable as a desirable trait of probiotics (Begley et al. 2006).  However, secondary bile acids 
that are produced from the multistep process of 7 α-dehydroxylation (alpha-dehydroxylation), 
subsequent to deconjugation, can accumulate and have been linked in humans to gallstones, 
colon cancer, and other gastrointestinal illnesses (Pavlović et al. 2012).  Regardless of whether 
or not humans may benefit from a BSH-mediated hypocholesterolemic effect, malabsorption of 
lipids may deter growth in production animals, particularly in poultry which derive a substantial 
percentage of energy from dietary lipids and thus rely on efficient fat digestion (Knarreborg et 
al., 2004). 
Feighner and Dashkevicz (1987) provided early evidence that antibiotic feed additives 
affect the transformation potential and hydrolysis activity of BSHs from intestinal contents of 
poultry.  By keying in on a more specific aspect of lipid metabolism, Knarreborg et al. (2004) 
demonstrated an enhanced bioavailability of α-tocopheryl (alpha-tocopherol) acetate in broilers 
given AGP, and this was attributed to a reduced concentration of unconjugated bile salts.  
Furthermore, Guban and colleagues (2006) correlated dietary supplementation of AGP to 
improved weight gain and fat digestibility in broilers, decreased population levels of 
Lactobacillus salivarius, and a reduced pool of deconjugated bile salts.  Based on these 
discoveries, the growth promoting effect of AGP likely is attributed to the reduced BSH activity, 
and thus the improvement of host lipid metabolism.  
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Functions and characteristics of bile salt hydrolase 
 Microbial BSH is a member of the choloylglycine hydrolase family of enzymes and is 
predominantly associated with gastrointestinal bacteria of both humans and animals. 
Additionally, it is classified as an N-terminal nucleophilic hydrolase and can recognize substrate 
at both the amino acid conjugate or steroid nucleus (Patel et al. 2010).  Bile salt hydrolase is 
particularly abundant in lactic acid fermenting probiotic stains like lactobacilli and bifidobacteria 
although certain pathogenic strains possess bsh homologs in their genomes (Begley et al. 2006).  
From studies which have purified and characterized BSH from different microorganisms, it is 
generally found that the enzyme is located intracellularly, oxygen insensitive, and optimally 
active at a slightly acidic pH (Pavlović et al. 2012).   
As previously stated, the enzymatic function of BSH is to catalyze deconjugation of bile 
salts, but there are several explanations as to how this benefits the bacteria that produce it.  One 
reason may be that BSH-producing strains derive nutritional advantages in the form of liberated 
amino acids released from the deconjugation reaction that could be used as carbon, nitrogen, and 
energy sources (Begley et al. 2006).  Another suggestion is that BSH facilitates cholesterol or 
bile incorporation into the bacterial membrane to improve its structural integrity against host 
immune defenses (Patel et al. 2010).  The most likely role for BSH activity, however, is that it 
aids in bile detoxification and gastrointestinal persistence (Kim & Lee 2005).  Bile is a natural 
detergent with antimicrobial activity which is largely aimed at dissolution of bacterial 
membranes (Begley et al. 2005) so naturally GI bacteria must have some mechanism to combat 
this threat and persist in their natural environment.  Bustos et al. (2012) investigated the role of 
BSH positive strains to withstand bile toxicity and proposed that by deconjugating primary bile 
acids, lactic acid bacteria were able to avoid intracellular acidification associated with 
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protonated, conjugated bile acids and subsequently avoid collapse of the proton motive force.  
Furthermore, in agreement with the previous work of Grill et al. (2000), it was found that BSH 
negative strains experienced significant cell death by cytoplasmic acidification after being 
exposed to both glyco- and tauro-conjugated bile acids whereas the BSH positive strains were 
only affected by high concentrations of glyco-conjugated bile acids, which are more toxic at 
acidic pH values.  This is not surprising since most BSH producing microbes prefer hydrolyzing 
glycine rather than taurine conjugates (Pavlović et al. 2012); however, some exceptions have 
been characterized (Hae-Keun et al. 2008; Chae et al. 2012). 
 In a metagenomic analysis of BSH activity in the human gut, Jones et al. (2008) 
demonstrate that conjugated bile acid has been the selective pressure driving the gut-associated 
microbiome toward BSH activity.  Interestingly, to further improve their ability to thrive in the 
harsh conditions of the GI tract by mechanisms just described and perhaps those which are not 
fully understood, many bacterial strains possess more than one bsh homolog in their genomes 
(Pavlović et al. 2012).  Research has shown that there are five amino acid sites that are highly 
conserved in the catalytic site of BSH (Begley et al. 2006). Even with such strict conservation, 
among distinct functional BSHs in the same strain, there is variation in their relative activity and 
substrate preference (Coleman & Hudson 1995; Hae-Keun et al. 2008; Lambert et al. 2008; Ren 
et al. 2011; Chae et al. 2012).  In some cases multiple bsh genes from one strain show greater 
similarity to those from other strains or species than with each other, indicating that horizontal 
gene transfer may play a role in bsh acquisition (Lambert et al. 2008).  Ren and colleagues 
(2011) noted that differences in bsh gene expression and protein function may be the cause of 
regulation factors and that substrate specificity could be the result of currently unrecognized 
binding or catalytic sites.  
13 
 
 
CHAPTER II 
INTRODUCTION 
 
Antibiotic growth promoters (AGP) are defined as a group of antibiotics delivered in 
animal feed at subtherapeutic levels to increase feed efficiency and average daily weight gain in 
food animals (Dibner & Richards 2005).  For more than fifty years this has been a standard 
practice of animal husbandry and measurable benefits to animal production are still apparent.  
Although these benefits were once believed to come at no appreciable risk, epidemiological 
studies have  suggested that antibiotic resistant bacteria are associated with the use of AGP, so 
what was once regarded as a benign approach to produce robust food animals is now considered 
a hazard to public health (Marshall & Levy 2011).  Indeed, such resistant bacteria can be 
transferred to humans as a result of direct contact or through more complicated, indirect means 
(van den Bogaard & Stobberingh 1999).  Recognizing that zoonotic reservoirs of drug-resistant 
bacteria constitute definite concern for animal as well as human safety, the European Union 
banned all AGP in 2006 and this approach has now become a worldwide trend (Marshall & Levy 
2011).  The transition to AGP-free production systems was in many regards successful, yet it 
proved to be challenging for some countries where animal health was compromised as a result 
(Casewell et al. 2003).  Completely eradicating AGP will present obstacles on the level of farmer 
to feed industry; thus, in order to maintain high-quality food animals and current production 
levels, it is essential that valid alternatives to AGP be discovered which do not pose a threat to 
public health, are able to promote feed efficiency, and are economically viable. 
Understanding how AGP exert growth promotion is critical to developing effective 
replacements.  Although the exact mode of action is unclear, it is commonly accepted that AGP 
modulate the host intestinal microflora, as their antibacterial nature would suggest, and thereby 
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generate optimal conditions for animal growth to occur (Marshall & Levy 2011; Dibner & 
Richards 2005; Barton 2000).  Recent studies using swine and poultry have helped us to 
understand the relationships between AGP supplementation and gastrointestinal bacterial 
composition (Knarreborg et al. 2002; Collier et al. 2003; Dumonceaux et al. 2006; Wise & 
Siragusa et al. 2007; Rettedal et al. 2009; Danzeisen et al. 2011; La-ongkhum et al. 2011; Kim et 
al. 2012; Lin et al. 2013).  The results of such studies prove that AGP create bacterial shifts and 
alter the microbial diversity of the intestine, indicating that certain populations may be more 
favorable to animal growth than others.  Simultaneously, these findings suggest that populations 
reduced by AGP are potentially harmful to animal performance and could be targeted by non-
antibiotic therapy.      
Although the definitive gut microbial community required for AGP-mediated optimal 
growth promotion is still largely unknown, previous studies have shown that the ability of AGP 
to promote growth is highly correlated with a decrease in activity of bile salt hydrolase (BSH) 
(Feighner & Dashkevicz 1987; Knarreborg et al. 2004; Guban et al. 2006; Hunkapillar et al. 
2009).  BSH is an enzyme produced by commensal bacteria in the intestine whose main function 
is to convert conjugated bile salts into unconjugated bile salts.  The exact purpose for which 
microbes utilize this enzyme is still uncertain, but several theories exist to explain its importance; 
these include roles in bile detoxification, gastrointestinal persistence, microbial nutrition, and 
alterations to bacterial membrane characteristics (Begley et al. 2006).  Regardless of the natural 
function of BSH for its bacterial producers, the impact of BSH on the host is clear.  
Unconjugated bile acids are amphipathic and able to solubilize lipids for micelle formation, 
however, when the amide bond is hydrolyzed by BSH, the resulting unconjugated form is much 
less efficient at doing so.  Thus, BSH effectively transforms bile salts that promote efficient lipid 
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solubilization into those that adversely affect lipid metabolism and subsequent energy harvest.  
Therefore, the probable mechanism in which AGP promote growth is to inhibit the activity of 
BSH that are produced by gut microflora and consequently confer positive conditions for lipid 
metabolism and utilization.  Lactobacilli are the primary inhabitants of the chicken intestine and 
are primary BSH producers in the gut (Begley et al. 2006; Guban et al. 2006).  Notably, L. 
salivarius, the dominant Lactobacillus species present in the chicken intestine, was reduced in 
response to AGP treatment (Engberg et al. 2000; Knarreborg et al. 2002; Guban et al. 2006; 
Dumonceaux et al. 2006; Zhou et al. 2007).  Based on these findings, inhibition of BSH activity 
using specific inhibitors is likely a promising approach to improve growth performance of food 
animals. 
Recently, Wang et al. (2012) identified and characterized a bsh gene from L. salivarius 
B30514, a BSH producer isolated from chicken intestine (Stern et al. 2006).  Characterization of 
this BSH strongly supported our hypothesis for developing BSH inhibitor-based feed additives as 
alternatives to AGP and established a solid platform for us to discover novel BSH inhibitors.  In 
this project, the following three specific objectives were pursued:  
1. Purify recombinant BSH and perform enzymatic characterization. 
2. Determine the inhibitory effects of various dietary factors on BSH activity. 
3. Develop and perform a rapid, convenient, and high-throughput assay for discovery of       
      BSH inhibitors.  
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CHAPTER III 
MATERIALS AND METHODS 
 
 
Preparation of lysates for His-tagged BSH purification 
 The recombinant BSH (rBSH) used in this study was purified from an E. coli construct 
(JL885) expressing a bsh gene originally from L. salivarius B-30514(Wang et al., 2012).  To 
prepare cell lysate for rBSH purification, the JL885 stock was streaked on a Luria-Bertani (LB) 
agar plate supplemented with ampicillin (100 µg/ml [microgram/milliliter]).  After overnight 
growth, a single colony was picked and inoculated into 50 ml of LB broth containing 100 µg /ml 
of ampicillin.  The culture was grown in a rotary shaker at 37°C overnight.  All of the 50-ml 
overnight culture was transferred to 1L of LB broth containing 100 µg/ml of ampicillin and 
grown in a rotary shaker (250 rpm) at 37°C until the optical density at 600 nm (O.D.600) reached 
0.5-0.6 (~2 hr).  To induce the production of rBSH, isopropyl-beta-D-thiogalactopyranoside 
(IPTG) (100 mM) was added to a final concentration of 0.5mM to the remaining early-log phase 
culture.  After 3 hours of induction, the cells were harvested by centrifugation at 5,000 × g at 4°C 
(Avanti J-26 XP Centrifuge, Beckman Coulter) for 20 minutes, and the pellets were washed with 
cold phosphate buffered saline (PBS) (pH 7.0).  The PBS-washed cell pellets were resuspended 
in 30 ml of ice cold lysis buffer (50 mM sodium phosphate buffer, 300 mM NaCl, 10 mM 
imidazole, pH 7.0) supplemented with 2 mM beta-mercaptoethanol (β-ME), 5 mM of adenosine 
triphosphate (ATP), 5 mM of MgCl2 (magnesium chloride), and 1 mg/ml of lysozyme.  The 
resuspension was transferred into a clean polystyrene tube and put on ice for 1 hour. The cell 
suspension was disrupted by sonication for 5 cycles (alternating between 30 s on and 60 s off; 
50% duty) on ice/NaCl mixture. The lysate underwent centrifugation at 12,000 rpm for 30 
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minutes at 4°C using a Beckman centrifuge equipped with a JLA rotor. The supernatant (soluble 
fraction), containing rBSH, was transferred into a clean polystyrene tube for further purification. 
 
Purification of His-tagged rBSH by Ni-NTA affinity chromotagraphy 
Approximately 2.5 ml of settled nickel-nitrilotriacetic acid (Ni
2+ 
-NTA) agarose resin 
(Qiagen) was equilibrated with the same lysis buffer used for cell pellet resuspension by washing 
three times with 5 ml of lysis buffer and centrifugation at 3,000 rpm for 1 minute after each 
wash.  The above bacterial lysate was mixed with the lysis buffer-treated Ni-NTA agarose resin 
with gentle rocking for 60 minutes at 4°C.  The mixture was loaded into a column and the flow 
through was collected.  The column was washed with 5 bed volumes of wash buffer (50 mM 
sodium phosphate buffer, 300 mM NaCl, 60 mM imidazole, 10% glycerol, pH 7.0) 
supplemented with 2 mM β-ME, 5 mM of ATP, and 5 mM of MgCl2 with flow through 
collected.  The proteins bound to the Ni-NTA were then eluted from the column with 5 bed 
volumes of elution buffer (50 mM sodium phosphate buffer, 300 mM NaCl, 300mM imidazole, 
10% glycerol, pH 7.0) supplemented with 2 mM β-ME (2 µl/100 ml buffer) and approximately 1 
ml of eluent was collected per tube.  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) with a 12% (wt/vol) polyacrylamide separating gel was performed to monitor 
production and purification of the rBSH. The rBSH-containing fractions were pooled and 
dialyzed against PBS buffer (50 mM, pH 7.0) containing 10% glycerol.  β-ME was then added to 
a final concentration of 2 mM.  The dialyzed rBSH was aliquoted into clean sterile tubes and 
stored at -80°C prior to use.  Protein concentration was measured by a bicinchoninic acid (BCA) 
protein assay kit (Pierce). 
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BSH activity assay 
Determination of BSH activity was performed by following a two-step procedure 
(Tanaka et al.,2000) to determine the amount of liberated amino acids from glycoconjugated and 
tauroconjugated bile salts (purchased from Sigma).   For the first step, the following components 
were combined in clean 1.5 ml plastic microcentrifuge tube to a final volume of 200 μl: 178 μl of 
reaction buffer (0.1 M sodium-phosphate, pH 6.0), 10 μl of purified rBSH (diluted to 1 µg/µl 
with reaction buffer), 10 μl of a particular conjugated bile salt (100 mM), and 2 μl 1M 
dithiothreitol (DTT).  This mixture was vortexed gently and incubated in a 37°C water bath for 
30 minutes.  Following incubation, 50 μl of reaction mix was immediately transferred to a clean 
microcentrifuge tube containing 50 μl of 15% (wt/vol) trichloroacetic acid (TCA) to stop the 
reaction.  After centrifugation at 12,000×g for 5 minutes to remove precipitate, 50 μl of 
supernatant was transferred to a clean 1.5 ml microcentrifuge tube for the second step.  To this, 
950 μl of ninhydrin reaction mix (0.25 ml of 1% [wt/vol] ninhydrin in 0.5 M sodium-citrate 
buffer [pH 5.5], 0.6 ml of glycerol, and 0.1 ml of 0.5 M sodium-citrate buffer [pH 5.5]) was 
added and vortexed to mix thoroughly.  The resulting reaction mix was incubated in a boiling 
water bath for 14 minutes and cooled on ice for 3 minutes to stop the reaction.  The absorbance 
at 570 nm (A570) was measured with a Smart Spec Plus spectrophotometer (Bio-Rad).  A control 
without BSH was set up simultaneously in each independent experiment.  A standard curve using 
glycine or taurine was performed for each independent assay.  All experiments were performed 
in triplicate.  The BSH activity was expressed as 1 μmol (micromole) of amino acids liberated 
from the substrate per minute per mg of BSH. 
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Effect of pH and temperature on the activity of rBSH 
 To determine the temperature dependence of rBSH activity, the assay was carried out as 
described above in 0.1 M sodium phosphate buffer (pH 6.0) at various temperatures ranging 
from 20 to 75°C.  Likewise, the optimal pH for rBSH activity was determined by performing the 
assay at pH values ranging from 3.0 to 8.0 using 0.1 M sodium citrate-citrate acid buffer (pH 3.0 
to 5.4) or 0.1 M sodium phosphate buffer (pH 6.0 to 8.0).  Both pH and temperature assays were 
performed using the standard procedure with glycocholic acid as the substrate.  All experiments 
were run in triplicate.  
 
Effect of dietary compounds on the activity of BSH 
 A panel of dietary compounds, many of which have been used as feed additives for food 
animals, was used in a BSH activity assay at a final concentration of 5 mM to determine if they 
were able to inhibit enzyme activity.  The following compounds were tested:  CuCl2 (copper 
chloride), ZnCl2 (zinc chloride), MnCl2 (manganese chloride), FeCl3 (ferric chloride), CaCl2 
(calcium chloride), MgCl2 (magnesium chloride), CoCl2 (cobalt chloride), KCl (potassium 
chloride), NaCl (sodium chloride), KI (potassium iodide), NaI (sodium iodide), Na2SeO3 
(sodium selenite), CuSO4 (cupric sulfate), FeSO4 (ferrous sulfate), MnSO4 (manganese sulfate), 
ZnSO4 (zinc sulfate), NaSO4 (sodium sulfate), MgSO4 (magnesium sulfate), KIO3 (potassium 
iodate), NaIO3 (sodium iodate), NaIO4 (sodium periodate), NaHCO3 (sodium bicarbonate), citric 
acid, ascorbic acid (vitamin C), cholecalciferol (vitamin D3), α-tocopherol (vitamin E), retinol 
(vitamin A), stearic acid, linolenic acid, linoleic acid, sodium acetate, sodium propionate, sodium 
lactate, and sodium butyrate.   We also tested the effect of several different switchgrass extracts 
on BSH activity.  Switchgrass (Panicum virgatum) is considered to be a potential feedstock used 
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to bioprocess liquid fuels like ethanol and is suggested as such under the UT Biofuels Initiative 
(Garland, UT Extension 2010).  Since cellulosic biomass is used directly for biofuel production, 
up to 20% of the extractives are left over, which could potentially be used in other applications to 
add value to the product as a whole.   The switchgrass extracts, which were previously dried and 
prepared using pressurized liquid extraction with water or 95% ethanol, were kindly provided by 
Dr. Niki Labbé of the UT Center for Renewable Carbon for use in our enzymatic assays.  
Prior to the addition of sodium glycocholate to the reaction mix, the rBSH was incubated 
with or without a particular compound for 30 minutes in a 37°C water bath.  Subsequently, the 
standard enzyme assay was performed as described above.  A control with no added compound 
was set up in each independent assay.  All assays were run in triplicate.  The percentage of 
inhibition was calculated by dividing the inhibited activity (calculated by subtracting the mean 
residual activity in the presence of a compound from the mean activity of the control) relative to 
the mean activity of the control and then multiplied by 100. 
 
Development of a high-throughput BSH assay 
 In order to move towards creating a rapid method of screening for BSH inhibitors, our 
standard BSH activity assay was adapted for use in a 96-well plate, similar to a procedure 
described by Tanaka et al. (2000) but with modifications. This is a precipitation assay which is 
based on the fact that hydrolysis of conjugated bile acid substrates will produce deconjugated 
bile acids which are insoluble at the reaction pH and can easily be visualized as a white 
precipitate; this feature provides a great advantage to develop a rapid and convenient HTS 
system to identify potent BSH inhibitors.  For initial assays, rBSH (10 μl [1μg/1μl]) was added to 
the bottom of a clear 96-well microtiter plate with a round bottom.  To this, 190 μl of reaction 
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mix (178 μl of reaction buffer [0.1 M sodium-phosphate, pH 6.0], 10 μl of a particular 
conjugated bile salt [100 mM], and 2 μl 1M DTT) was added for a total reaction volume of     
200 μl.  Plates were incubated at 37°C for up to 6 hours.  Precipitation of insoluble unconjugated 
bile salts was monitored every 30 minutes by visual observation concomitant to absorbance 
measurement at 600 nm (A600) using a microplate reader (model Multiskan EX; Thermo Fisher 
Scientific, Vantaa, Finland).  For subsequent assays, different parameters were altered to 
determine the optimal assay conditions.  BSH was added in 10 μl amounts diluted from stock 
concentration (8 μg/μl) from 2 to 300-fold; pH values of 6.0 or 6.5 were tested using 0.1 M 
sodium phosphate buffer (pH 6.0) or 0.05 M sodium phosphate buffer (pH 6.5); incubation was 
tested at room temperature (20°C), 37°C, or 40°C; glyco- and tauro-conjugated substrates were 
tested at final concentrations ranging from 0 mM to 50 mM.   
After the assay conditions were optimized for the 200 μl reaction in a 96-well plate, we 
confirmed the ability of this procedure to screen compounds for BSH inhibition by a proof of 
concept assay using known BSH inhibitors. Before adding the reaction mix, 10 μl of known 
inhibitor was added to the BSH in the bottom of each well and mixed gently by pipetting.  
Inhibitors were added at an initial 10 mM concentration and subjected to twofold serial dilutions 
up to 9 times through column 10 of the plate.  As a control, two columns on each plate served as 
controls:  a positive control with BSH and reaction mix only and a negative control with no 
added BSH or inhibitor.  Assays were performed in duplicate.  After all conditions were 
optimized, including use of inhibitors, the entire reaction was scaled down to a 50 µl total 
volume and modified accordingly for a future preliminary HTS library screen at Vanderbilt 
University.  An additional assay was performed using dimethyl sulfoxide (DMSO), the library 
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compound solvent, as a control to ensure that it did not negatively affect the ability of BSH to 
effectively hydrolyze substrate.  
 
High-throughput screening of BSH inhibitors 
 High-throughput screening (HTS) of BSH inhibitors was performed at the HTS facility at 
the Vanderbilt Institute of Chemical Biology (Nashville, TN).  The library (2,240 compounds in 
7 source plates from Spectrum) includes biologically active and structurally diverse compounds 
of known drugs, experimental bioactives, and pure natural products. All compounds tested were 
dissolved in DMSO at a concentration of 10 mM.  Briefly, 0.25 μl of a specific compound from 
the Spectrum Collection library was shot into the bottom of a clear 384-well microplate (Greiner 
cat # 781182) with flat bottom using the Echo 550/555 (Labcyte).    Next, 12.5 μl of BSH 
(diluted 50x from a stock concentration of 8 μg/μl) was added using the Multidrop Combi 
reagent dispenser (Thermo Scientific) and shaken for 5 minutes.  Finally, 37.5 μl of reaction mix 
(32 μl reaction buffer [0.1 M sodium-phosphate, pH 6.0], 2.5 μl of taurodeoxycholic acid [200 
mM], and 0.5 μl of 1M DTT) was added using the Multidrop Combi for a total reaction volume 
of 50 μl.  The plates were subsequently shaken for 5 minutes to insure thorough mixing and spun 
to pull any reaction mixture back into the bottom of the well before incubation.  Plates were 
incubated at 37°C with humidity and 5% CO2 and absorbance measured every hour at 600 nm 
(A600) for 4 hours using a SpectraMax M5 (Molecular Devices) with temperature controlled at 
37°C; visual observations were concomitantly documented for precipitation. The reader on the 
system is connected via intranet to the facility’s network, enabling automated data acquisition, 
analysis, visualization, and archival using a powerful management and chemiinformatics tool, 
Accelrys Pipeline Pilot; all data are stored in an Oracle database.  Each plate contained three 
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controls manually added with a multichannel pipette in a predetermined pattern to the side wells.  
Control 1 consisted of BSH, DMSO, and reaction mix; control 2 contained a known inhibitor, 
BSH, and reaction mix; control 3 contained DMSO and reaction mix only.  Validation plates 
were also tested using known inhibitors prior to HTS of the compound libraries to ensure 
reproducibility of the assay in a new setting. 
 
Selection and in vitro validation of identified BSH inhibitors. 
 A preliminary list of BSH inhibitor hits was generated after the above HTS based on the 
dynamics and magnitude of precipitation formation in each well (reflected by OD600).  Extensive 
review of relevant material safety data sheet (MSDS) and literature were performed for the hits 
with emphasis on availability, stability, toxicity, cost, and environmental impact.  Notably, the 
hit compounds belonging to an antimicrobial family were eliminated and will not be considered 
for further evaluation because of the well-known food safety issue related to antimicrobial 
growth promoters. 
 The selected BSH inhibitor candidates were subjected to further in vitro validation using 
the 96-well microplate assay and the standard 2-step BSH assay as described above. The 
standard BSH assay is essential to confirm if the identified compounds are indeed real BSH 
inhibitors because we cannot completely rule out a possibility that certain compounds may cause 
less or no precipitation in reaction mix in a BSH activity-independent manner. 
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CHAPTER IV 
RESULTS 
 
 
Expression and purification of rBSH from E. coli 
To obtain sufficient rBSH for enzymatic characterization and screening of BSH inhibitors 
for this project, large quantities of rBSH were produced and purified.  As early as one hour after 
IPTG induction, a significant amount of rBSH was produced, reflected by the presence of 
additional protein band with a molecular mass of 37 kDa on SDS-PAGE (Fig. 1, lane 3).  Using 
1-step Ni-NTA affinity chromatography, large quantities of high purity C-terminal His-tagged 
rBSH were obtained, as seen in different eluent fractions (Fig. 2, lanes 6-10).  Fractions 
displaying the highest BSH quantities (e.g lanes 6-8 in Fig. 2) were pooled together for dialysis 
against PBS.  From 1 liter of induced culture, the purification procedure yielded approximately 
15 mg of rBSH. 
 
Substrate preference of rBSH 
 Using the standard BSH activity assay, six different bile salts were tested to determine 
the substrate specificity (Table 1).  Overall, the rBSH displayed a broad substrate affinity and 
was able to hydrolyze both the glycine and taurine conjugates.  The highest hydrolysis activity 
occurred when glycochenodeoxycholic acid (defined as 100% activity) was used as the substrate.  
However, in examining the activities given other substrates, there was no clear preference for the 
other glycoconjugated bile salts compared to the three tauroconjugated bile salts tested.  The 
relative activities of the remaining bile salts ranged from 22.3% to 47.9% (Table 1).  
Furthermore, among the different substrates, the BSH showed no obvious preference among 
conjugated cholic, deoxycholic, or chenodeoxycholic acids.    
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Effect of pH and temperature on rBSH activity 
 The effect of pH on rBSH activity was determined by conducting the standard activity 
assay at different pH values ranging from 3.0 to 8.0 using either 0.1 M sodium citrate-citrate acid 
buffer or 0.1 M sodium phosphate buffer (Fig. 3).  Optimal activity was observed between pH 
values of 5.0 and 6.0, with maximal activity occurring at a pH of 5.4.  Moderate activity was still 
evident at pH limits of 4.4 and 6.4, but as pH declined or increased beyond these measures, BSH 
activity greatly declined and was almost negligible at a pH of 8.0.  We also tested BSH activity 
at temperatures ranging from 25°C to 75°C and found that peak activity occurs at 41°C (Fig. 4).  
Activity was stable from 35°C to 55°C but experienced a dramatic drop when the temperature 
exceeded 55°C.  Following the 30 minute incubation, at our lowest temperature tested (22°C), 
BSH lost approximately 52% of its activity, whereas, at the upper extreme of 75°C the activity 
had diminished by nearly 90% of original activity. 
 
Identification of dietary compounds inhibitory to the activity of rBSH. 
 Various compounds that are used as dietary supplements in animal feeds were selected 
for determination of their ability to inhibit BSH activity.  As shown in Table 2, it is clear that 
several compounds, such as CuCl2, CuSO4, FeSO4, CoCl2, NaSeO3, NaIO4, KIO3, retinol, and 
linolenic acid, were potent inhibitors, having greater than 90% inhibition.    In contrast, some 
compounds tested actually improved the catalytic activity of the rBSH, such as citric acid (Table 
2).  In addition, several switchgrass extracts (Panicum virgatum) representing collection at 
different growth stages and location were screened.  All samples tested, which included both 
ethanol and water extracted components, enhanced BSH activity by 10.5 to 35.1% when tested at 
a 50-fold dilution (data not shown).   
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Optimization of a HTS system to determine BSH inhibitors 
 To determine optimal conditions for a HTS system, the standard BSH activity procedure 
was performed in a 96-well plate.   pH, temperature, substrate concentration, and incubation 
length were altered in separate assays for assessment.  As expected, a pH of 6.0 and an 
incubation temperature of 37°C, both of which are used in the standard 2-step assay, were 
conducive to efficient BSH hydrolysis.  However, regarding substrate choice, it was found that 
taurodeoxycholic acid rather than glycocholic acid was much better at eliciting an observable 
activity response; additionally, a final substrate concentration of 10 mM produced ideal results.  
An incubation length of 2 to 4 hours was targeted in order to get several progressive 
measurements during the development of precipitation; using 10 µl of undiluted BSH (8 µg/µl) 
caused the reaction to proceed too quickly so it was diluted by factors of 5 up to 300.  It was 
determined that a 50-fold dilution (10 µl) was sufficient to elicit adequate hydrolysis of substrate 
with maximal precipitation occurring after approximately 2 hours of incubation in a 200 µl total 
reaction volume.  Changes were easily able to be observed visually, as insoluble deconjugates 
precipitated and results were able to be corroborated by additional measurements using a 
microplate reader.  The control wells without the addition of BSH further confirmed our assay 
validity by remaining clear and consistently producing only a background spectrophotometric 
measurement.   
With the above parameters optimized, a proof-of-concept experiment using known BSH 
inhibitors was performed.  As shown in Fig. 5, in the presence of high levels of specific potent 
BSH inhibitor (e.g. A1-A5 & B1-B5 for NaIO4, E1-E4 & F1-F4 for NaIO3), the activity of BSH 
was inhibited, which was reflected by displaying clear, transparent wells.  In the presence of low 
concentrations of the BSH inhibitor and in the absence of the BSH inhibitor (right section except 
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the far right negative control wells, Fig. 5), the reaction mix became turbid due to the 
precipitation of unconjugated bile salts due to BSH activity.  The other two iodide compounds, 
NaI and KI, displayed lower inhibitory effect than NaIO4 and NaIO3 (Fig. 5), which is consistent 
with the results using quantitative 2-step assay (Table 2).  Although the copper and zinc 
compounds were potent inhibitors at higher concentrations in our 2-step assay (Table 2), they 
tended to form aggregates at high concentrations after prolonged incubation in the plate assay; 
furthermore, they were less inhibitive at lower concentrations than were the iodate compounds 
(Fig. 6, A-D rows).  Similarly, Na2SeO3 aggregated even at a starting concentration of 10 mM 
and 5 mM (Fig. 6).  After several stepwise dilutions this effect was diminished and Na2SeO3 still 
clearly inhibited BSH activity at low concentrations, but the aggregation potential negates its 
usefulness as a control compound (Fig. 6).   KIO3 appears to be an ideal control inhibitor for 
HTS due to its ability to inhibit BSH activity at low concentrations and consistently show a dose 
dependent response with high clarity (Fig. 6).  After modifying the dilution factor, it was 
subsequently concluded that a starting compound (KIO3) concentration of 10 mM (10 µl per 
well) was adequate to inhibit activity and 2-fold dilutions in nine successive wells were used to 
show a dose dependent response.   
The assay was further scaled down the assay to a 50 µl total reaction volume, which is 
required for HTS, using 384-well plates.  A prolonged incubation length (3-4 hours) was needed 
for precipitation to fully develop.  Additionally, an experiment was done to insure that DMSO, 
the solvent used for HTS library compounds, was itself not inhibitory to BSH.  It was found that 
there was negligible interference of DMSO (final concentration of 50 mM) on precipitation 
formation (data not shown). 
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HTS discovery of BSH inhibitors 
 At the HTS facility at the Vanderbilt Institute of Chemical Biology, all assays were 
performed in a scaled down 50 µl total reaction volume for use in a 384-well plate, the format of 
which their compound libraries are stored and routinely used for other HTS assays.  One day 
prior to screening of the compound libraries, validation assays containing different controls were 
carried out to ensure the system was optimal for actual inhibitor screening and that the optimized 
conditions translated well to this HTS format.  Several plate layouts were designed and included 
in selected controls were either KIO3 or NaIO4, inhibitors routinely used in the 96-well assays, 
and DMSO.  The results of these test plates indicated that the assay could clearly distinguish 
between wells with or without precipitation as a result of BSH hydrolysis.  Both negative 
controls (no BSH) and those using NaIO4 and KIO3 remained clear in stark contrast to positive 
controls (no inhibitor) that displayed obvious precipitation (also confirmed by reading on the 
Spectramax).  The simple checkerboard layout of one such validation plate (Fig. 7), shows that 
the assay could clearly distinguish between wells with or without precipitation as a result of BSH 
hydrolysis and indicate that DMSO has no negative impact of the ability of BSH to hydrolyze a 
bile acid substrate.  Thus, we were able to undergo a pilot screening of a 2,240-compound library 
composed of structurally and functionally diverse compounds.  It should be noted that for the 
actual HTS screen, BSH was diluted with buffer containing 3 mM of DTT to prevent oxidation 
of BSH enzyme during a prolonged incubation period between setup of assays; this modification 
improved enzyme stability and visible hydrolysis.  A total of 7 plates were used for this 
screening, which was very successful and has led to 107 hits that were considered potent 
inhibitors.  Hits were confirmed based on visual observation (Fig. 8) and corroborated via 
spectrophotometric measurement.   
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Preliminary review of biochemical information of the corresponding hits eliminated most 
of compounds and led to a 10-compound list (Table 3).  These 10 compounds were subjected to 
further validation using the plate assay as well as the 2-step activity assay to ascertain the 
quantitative inhibitory effect; these included phenethyl caffeate (also called ‘caffeic acid 
phenethyl ester’, CAPE), carnosic acid, chrysophanol, epicatechin monogallate, gossypetin, 
purpurogallin, riboflavin, theaflavanin, folic acid, and menadione.  The ten compounds selected 
for further testing were purchased directly from Vanderbilt, which have been solubilized in 
DMSO; compounds were stored at -20°C after arrival.  Ninety-six-well plate assays were first 
conducted to test repeatability of results from the original HTS screen.  Each compound was 
tested at an initial concentration of 10mM.  Although most compounds displayed inhibitory 
activity even after the first dilution, several did not display inhibitory effect as expected (folic 
acid, chrysophanol, CAPE, epicatechin monogallate, and theaflavanin), particularly since the 
library compounds were initially screened using 0.25 µl (10mM) rather than the 2.5 µl (10mM) 
we routinely use in our laboratory.  Plate assays were repeated to confirm these findings, and it 
was consistently noted that chrysophanol and folic acid had no inhibitory effect on BSH and 
CAPE, epicatechin monogallate, and theaflavanin appeared only to inhibit at the highest 
concentrations tested (final concentrations of 0.5, 0.25 mM).  Compounds showing greater 
inhibition included carnosic acid, menadione, gossypetin, and riboflavin (Fig. 9).   
In addition to the above precipitation-based microplate assay, each compound was 
subsequently tested in the 2-step assay to determine a quantitative inhibitive response when used 
at a higher concentration; CuCl2 was included as a known inhibitor control, as demonstrated in 
the preliminary screen of dietary feed additives.  It was exciting to note that several of the 
compounds, despite a lower capacity to offer visual proof of inhibition using the plate method, 
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actually were able to inhibit BSH activity at relatively high percentages (Table 4).  Notably, 
CAPE and epicatechin monogallate consistently inhibited activity by over 90%, indicating they 
are potent BSH inhibitors.  Riboflavin, gossypetin, menadione, and carnosic acid, also displayed 
high ranges of inhibition, consistent with the plate assay.  Several of these compounds of 
particular interest were also tested at higher dilutions.  CAPE still inhibited rBSH activity by 
more than 85% at a final concentration of 0.625 mM; carnosic acid and riboflavin each inhibited 
at rates over 90% at a final concentration of 0.625 mM and 0.05 mM, respectively.  However, 
chrysophanol was very poor at inhibiting BSH hydrolysis and folic acid actually enhanced 
activity.  This indicates that while the HTS plate method is mostly accurate at revealing genuine 
BSH inhibitors, it is best to clarify these results using the quantitative BSH assay.   
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CHAPTER V 
DISCUSSION 
 
Antibiotic growth promoters (AGP) have undoubtedly had a positive influence on animal 
production since their early facilitation in the 1950s; however, the current concern over antibiotic 
resistance of zoonotic origin is the driving impetus for their discontinuation.  Different products 
have been proposed as alternatives for AGP, including essential oils, prebiotics, probiotics, 
enzymes, and organic acids, among others, to change gut microbiota for enhanced animal health 
and growth performance (Huyghebaert et al. 2011); however, very limited data is available to 
justify the choice of specific bacterial species or products for such microbiota manipulation. 
Exogenous enzymes have garnered much attention as one alternative to AGP.  Generally, 
these target non-starch polysaccharides like hemicellulose and β[beta]-glucans and have been 
noted to improve performance via enhanced diet digestibility and may also beneficially 
manipulate host microflora and immunity (Bedford 2000; Huyghebaert et al. 2011).  Although 
some recent studies do suggest improvements in poultry and swine health and performance (Jo et 
al. 2012; Zou et al. 2013), there are other studies which note no significant effect of enzyme 
treatments and even negative impacts on performance (Yegani & Korver 2013; Karimi et al. 
2013).  This lack of consistency is a notable drawback for dietary enzyme inclusion, and 
although it may improve nutrient digestibility, results will be highly variable depending on 
enzyme source, dietary form and quality, as well as dosage, intestinal uptake and availability, 
and animal age and breed.  Furthermore, many performance studies do not address how 
exogenous enzymes affect the intestinal microflora; improved digestion rates because of enzyme 
supplementation undoubtedly reduce the available substrate available for gastrointestinal 
bacteria, which could target harmful bacteria, but also negatively impact beneficial populations.   
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Probiotics, the live bacterial organisms, have also been extensively evaluated as potential 
AGP alternatives, particularly for poultry, and improvements in performance, gut mucosal 
immunity, and nutrient digestibility have been noted (Mountzouris et al., 2010).  However, 
introducing live microorganisms into the gut environment could potentially have unforeseen 
consequences.  Indeed, AGP generally target intestinal populations of gram-positive bacteria, 
including lactobacilli which have been commonly used as probiotic strains (Barton 2000; 
Gaskins et al. 2002; Sharifi et al., 2012); thus, there seems to be some disparity in the ultimate 
efficacy increased numbers may have on gastrointestinal health.  Certainly many considerations 
must be weighed, and administration level and frequency could be a point of contention.  For 
example, Mountzouris et al. (2010) tested the growth-promoting efficacy of a 5-bacterial strain 
probiotic and concluded that treatment at the lowest inclusion level tested resulted in the best 
performance, while higher levels actually lowered ileal digestibility coefficients.  Additionally, 
bird age and diet likely will pose challenges in developing probiotic strategies.  In a study 
conducted to evaluate differences between flavomycin and probiotics on dietary fat utilization, 
Sharifi et al. (2012) observed that “probiotics caused significant growth-depressing effects, 
inferior feed conversion, and reduced fat and GE [gross energy] digestibility irrespective of the 
source of dietary fat.”  They proposed that increased lactobacilli numbers greatly enhanced the 
deconjugation of bile salts caused by BSH activity, thereby reducing the ability to digest fat; 
furthermore, the young age of the birds meant they had limited pancreatic lipase secretion which 
rendered the effects of the probiotics disadvantageous. Therefore, the overall beneficial effects 
associated with specific probiotics should be carefully evaluated. Understanding the science of 
potential negative traits of probiotics can help us develop ‘negative-traits-mitigation’ strategies 
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to optimize probiotic products for enhanced growth performance of food animals and 
profitability of the feed additive industry. 
Various studies link AGP induced growth promotion with altered gastrointestinal (GI) 
microflora, but data are limited to provide compelling justification for which bacterial species 
should be modulated (Marshall & Levy 2011; Dibner & Richards 2005; Barton 2000).  Perhaps, 
then, it would be feasible to approach this issue at the cellular level by targeting general 
enzymatic activities and metabolite production influenced by AGP usage.  One such avenue 
worth pursuing is examination of bile salt hydrolase (BSH).  In 1987, Feighner and Dashkevicz 
observed an inverse relationship between BSH activity and growth performance in poultry 
supplemented with subtherapeutic doses of antibiotics; they further suggested that specific 
enzyme inhibitors could enhance growth and feed conversion in livestock and negate the need 
for antibiotic feed additives.  Although other studies have since corroborated these findings and 
agree that AGP usage decreases gut BSH activity (Guban et al. 2006; Knarreborg et al. 2004), 
there is a lack of published information regarding relevant attempts to identify BSH inhibitors.  
Alternatively, there is mounting evidence that AGP use greatly influences intestinal populations 
of Lactobacillus, prime BSH-producing commensals, by reduction of overall numbers or 
modulation of strain abundance (Knarreborg et al. 2002; Dumonceaux et al. 2006; Rettedal et al. 
2009); specifically, AGP use in broilers is associated with decreased populations of L. salivarius 
(Engberg et al. 2000; Knarreborg et al. 2002; Guban et al. 2006; Dumonceaux et al. 2006; Zhou 
et al. 2007).   Furthermore, Guban et al. (2006) proposed that because of its capacity for 
deconjugating bile salts and promoting decreased weight gain, L. salivarius would be a prime 
target to eliminate from the broiler intestine.  Building off of these published findings, in this 
study, a recombinant BSH (rBSH) from a chicken L. salivarius strain (Wang et al. 2012) was 
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used to perform preliminary enzyme characterization and initiate the discovery of BSH inhibitors 
via a standard quantitative assay as well as an efficient high-throughput screening (HTS) 
procedure. 
 Biochemical characterization of the rBSH from L. salivarius NRRL B-30514 revealed 
unique functional qualities.  Six different bile salts were tested to determine substrate preference.  
Although the enzyme showed the highest activity for glycochenodeoxycholic acid, the relative 
activities of the other glycine and taurine-conjugated bile salts were similar when compared to 
one another. Additionally, there was no major difference in activity against cholic, deoxycholic, 
or chenodeoxycholic acids.  Bile salt hydrolase enzymes produced by commensal bacteria tend 
to either have a broad or narrow substrate range and most often they have higher efficiencies at 
hydrolyzing glycoconjugated bile salts (Begley et al. 2006).  The rBSH used in this study 
displayed a broad substrate range and was able to efficiently hydrolyze both glyco- and 
tauroconjugated bile salts.  Its maximal activity occurred at a pH of 5.4, falling under the slightly 
acidic pH optima to which most BSH enzymes conform (Pavlović et al. 2012).  Interestingly, 
BSHs from different strains of the same species can have surprisingly different biochemical 
preferences.  Specifically, two BSH1 enzymes from L. salivarius UCC118 and JCM1046 had 
variable specific activities on a range of glycine and taurine conjugated bile salts (Fang et al. 
2009).  Although the rBSHNRRL B-30514 in this study effectively hydrolyzed a wide range of 
substrates, Bsh1UCC118  preferred glycoconjugated bile acids and showed limited activity for 
tauroconjugated bile acids whereas Bsh1JCM1046  had higher catalytic activities when the substrate 
was tauroconjugated.  Both BSH1 enzymes had broad pH optima, but maximum activity 
occurred at a pH of 5.5 or 6.5 for Bsh1JCM1046 and Bsh1UCC118, respectively.  These differences in 
substrate specificity and other hydrolysis kinetics may be linked to the internal deletion of 8 
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amino acid residues of Bsh1UCC118, considered to be in the conserved active site (Fang et al. 
2009).  Thus, our understanding of differences in phenotypic functionality of BSH enzymes from 
L. salivarius, or from any species in general, would likely benefit from future structural and 
comparative sequence analyses that may reveal key residues in the active site or other binding 
sites which may help to explain biochemical preferences. 
 As shown in this study, the rBSH of L. salivarius was able to efficiently hydrolyze a 
broad range of substrates.  This particular enzyme trait makes it an ideal candidate when 
screening for inhibitors, since any potential inhibitor would have to target a wide range of BSH 
enzymes, each with different substrate preferences and hydrolyzing capabilities.  From our initial 
screen using different feed additives and dietary trace minerals, we discovered several inhibitors 
with moderate or potent inhibition.  Of particular interest among these are the copper and zinc 
compounds.  Research has shown that adding high concentrations of dietary copper and zinc can 
improve growth performance and feed efficiency of poultry (Ewing et al. 1998; Miles et al. 
1998; Arias & Koutsos 2006; Liu et al. 2011) and swine (Smith et al. 1997; Armstrong et al. 
2004; Jacela et al. 2010; Shelton et al. 2011); in addition, supplementary zinc can improve the 
carcass traits and meat quality of broilers (Liu et al. 2011).  As of now, there is a lack of 
compelling scientific evidence used to explain a specific mechanism of action for how copper 
and zinc act as growth promoters, although it is loosely assumed to arise from their antimicrobial 
properties (Jacela et al. 2010).  However, there is an additive effect of adding high 
concentrations of copper along with AGP in the diet (Jacela et al. 2010), which suggests that 
there are other mechanisms at work outside of its antimicrobial effect.  Potentially the reason that 
copper and zinc can mimic the effects of AGP when given in high doses is that they are acting as 
intestinal BSH inhibitors and improving lipid digestion through maintenance of the pool of 
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conjugated bile salts.  While it is tempting to assume that high concentrations of copper and zinc 
would make adequate AGP replacements, there are several concerns about high levels of these 
metals being used long-term in animal feed.  The obvious problem is potential copper/zinc 
toxicosis due to prolonged exposure; likely the threshold for effective metabolism and absorption 
would depend on animal type and age as well as the dietary source.  Additionally, higher nutrient 
composition in the feed will be reflected in an increased amount excreted in the feces.  This can 
have undesirable repercussions on the environment, particularly for soil where manure with 
accumulated levels of copper and zinc are applied (Jacela et al. 2010), and it has been suggested 
that plants could develop toxicities if bulk quantities of manure were applied to a limited land 
area for an extended duration (Singh 2005).  Furthermore, metals that are frequently added in 
animal feed may co-select for antibiotic resistant bacteria, as Cavaco et al. (2011) observed that 
zinc resistance of zoonotic derived Staphylococcus aureus has a strong association with 
methicillin resistance.  For these reasons, careful consideration should be given when choosing 
novel inhibitors, such that negative impact to both animal and environment is minimized. 
  Besides copper and zinc, various other compounds in the preliminary screen also 
exhibited a large inhibitory effect on rBSH hydrolysis.  Retinol, a fat-soluble vitamin important 
for growth, vision, and immunity, was found to be a potent inhibitor, but it can potentially 
accumulate to toxic levels in many animal species so prolonged supplementation would not be a 
good option (National Academic Press, 1987).  A panel of iodate compounds also showed great 
inhibition (Table 2), but again, these warrant cautious justification for use as AGP alternatives.  
It is possible that high dietary concentrations of iodine may have multiple host effects, some of 
which may be undesirable.  As constituents of thyroid hormones, prolonged administration of 
iodate compounds at high levels could increase basal metabolic rate and consequently lead to 
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weight loss, negating the effect of inhibiting BSH activity.  One additive with potential from the 
preliminary screen is linolenic acid, which inhibited rBSH activity by approximately 90%.  
Linolenic acid (or α-linolenic acid) is one of several omega-3 polyunsaturated fatty acids which, 
collectively, are precursors of immune and inflammation mediators and play important roles in 
regulating membrane fluidity and in disease prevention and intervention (Connor 2000).  From a 
human perspective, supplementing chickens with α-linolenic acid may benefit poultry consumers 
since it can enhance omega-3 long chain polyunsaturated fatty acid levels in chicken tissues 
(Kartikasari et al. 2012; Haug et al. 2012).  In addition, linolenic acid can affect bone strength as 
Tarleton et al. (2013) found that supplementing free-range hens with α-linolenic acid improved 
skeletal health and reduced keel fractures.  However, this evidence needs corroboration since a 
previous, similar study found no effect of omega-3 supplementation on bone health as well as 
increased mortality compared to birds in a control group (Toscano et al. 2012).  Moreover, 
although there is little published information regarding solely how linolenic acid affects growth 
performance, it has been shown that feeding diets rich in fish oil omega-3 polyunsaturated fatty 
acids improves body weight gain in poultry (Geier et al. 2009).  Research regarding other 
omega-3 supplementation may be warranted.  
 The preliminary screen also identified several compounds which actually enhance BSH 
activity.  While these are not necessarily of interest relative to this study, compounds that 
improve the ability of BSH to hydrolyze conjugated bile salts could have potential human 
applications.  The capacity to hydrolyze bile salts has frequently been a criterion for probiotic 
strain selection because of the potential to lower blood cholesterol levels (Begley et al. 2006).  
As previously stated, deconjugated bile salts are less soluble and consequently less likely to be 
reabsorbed.  This lowers cholesterol solubility and absorption, and excretion in the feces will 
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necessitate an increased demand for cholesterol for de novo synthesis of more bile salts.  
Additionally, conjugated bile salts help expedite lipid metabolism and act as signaling molecules 
to regulate endocrine function and glucose homeostasis (Jones et al. 2008; Pavlović et al. 2012), 
so BSH has the potential to significantly impact host physiology and thereby reduce the risk of 
metabolic disorders such as diabetes and obesity.  The BSH enhancing compounds, therefore, 
could be used as a novel food additive to increase the activity of BSH in the intestine and 
facilitate health improvements in persons who are hypercholesterolemic or overweight.   
Because of the potentially confounding effects associated with several of the inhibitors 
discovered in the preliminary screen of dietary factors, the best way to identify powerful, safe, 
and cost-effective BSH inhibitors should involve large scale screening of diverse compounds 
including emerging feed additives.  An understanding of what contributes to successful enzyme 
inhibition, for example, competitive binding to the active site or allosteric hindrance, may lead to 
the utilization of computational techniques to identify these.  However, homology modeling and 
molecular docking would both require an accessible three-dimensional structure of important 
BSH enzymes, and many of these are currently unavailable, including one for the enzyme in this 
study.  Therefore, high-throughput screening (HTS) such as that used in drug discovery is 
currently the most promising avenue to pursue regarding BSH inhibitor identification.  
Additionally, HTS is beneficial because automating the BSH assay can greatly improve time 
efficiency and save money due to a lesser quantity of reagents needed.  For example, scaling the 
reaction down from a total volume of 200 µl to 50 µl reduces reagent use by 75%, and although 
the precipitation-based method requires four hours of incubation, setup and preparation times are 
comparable to the 2-step method.  The end result is that thousands of compounds are screened 
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simultaneously compared to only a handful; it would take weeks, if not months, to achieve these 
results using the standard assay, which relies on manual pipetting vs. a bulk reagent dispenser.      
Capitalizing on this idea, we successfully developed and validated such a HTS system in 
this project.  Although conjugated bile salts are soluble in aqueous solutions, upon hydrolysis via 
BSH, the resulting deconjugated version is insoluble and leads to significant precipitation that is 
evident to the naked eye.  This unique feature allowed us to modify our quantitative 2-step 
screen for a scaled down version that was amenable for use in multiple settings.  Specifically, the 
convenience of this precipitation-based screen allowed us to travel to the nearest HTS center to 
the University of Tennessee which is located at Vanderbilt University’s Institute of Chemical 
Biology.  There we were able to test out this new system by screening a diverse compound 
library for novel BSH inhibitors.  
Overall, the ability of the HTS system to detect rBSH inhibitors proved to be a reliable 
means of inhibitor detection.  The concept adapted well to Vanderbilt’s 384-well plate format in 
which their libraries are routinely screened for multiple purposes, and the opportunity to utilize 
some of their advanced instrumentation, namely the Echo 550/555, contributed greatly to the 
convenience and rapidity with which this assay could be carried out.  There are some minor 
complications that need to be addressed to improve efficacy of future screens.  Notably, not all of 
our featured compounds reacted as expected once validation assays were attempted.  
Chrysophanol and folic acid, both recognized as inhibitors in the library screen, subsequently 
only inhibited activity to a very small extent or even improved hydrolysis of substrate, 
respectively.  It is possible that these were false positives since we only had the time and 
resources to do one all-encompassing screen.  A second re-screen, including only a subset of 
compounds of interest, would have been beneficial in confirming our suspected compounds as 
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legitimate inhibitors.    Another possibility is that binding affinity of chrysophanol and folic acid 
to BSH may be lower than that of other compounds, and the extended shaking step at Vanderbilt 
could have improved the compound-enzyme interaction, whereas we rely only on manual 
pipetting to mix the two in our 96-well plate version; the additional large surface area to volume 
ratio of the wells of the 384-well plate could have contributed in this sense as well.   
Finally, it must be resolved why some of the compounds were positive HTS hits with 
further validation by standard 2-step BSH assay but produce confounding results when using the 
96-well plate assay in our laboratory.  For example, the cloudy appearance of wells including 
CAPE and epicatechin monogallate belied their potency as tested in the 2-step assay.  Since this 
effect was clearly not noted at Vanderbilt during the initial library screen, likely the solution 
stability or chemical properties may have been altered in transit or as a result of the freeze/thaw 
process which affected the way it behaved during the reaction.  Organic compounds dissolved in 
DMSO can dissolute or precipitate out after repeated freeze/thaw cycles or water uptake 
(Oldenburg et al. 2005).  Should CAPE, for example, have experienced partial dissolution, upon 
introduction into the aqueous buffer a precipitate may have formed which would be confused as 
precipitation as a result of bile salt deconjugation.     Although it may be a far-reaching 
conjecture, large-scale screening could be amenable to the discovery of compounds that behave 
in this fashion and create downstream confusion.  More consideration should be given to these 
and other possibilities that would ultimately lead to contradictions in assay results interpretation.           
The Spectrum Collection library that was screened contained a wide range of structurally 
diverse compounds, including drug components, natural products, and other bioactive 
constituents.  Although the library did contain known antibiotics which are obviously not of 
interest to us, the fact that many of them did inhibit rBSH activity is in support of our belief that 
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AGP contribute to decreased BSH activity and improved animal growth performance.  We 
further investigated and validated ten promising hits (Table 3).  Out of these ten compounds, 
several were strong inhibitors that possess intriguing beneficial qualities.   Carnosic acid and 
epicatechin monogallate are both nutraceuticals with noted antioxidant and neuroprotective 
effects (Terrao et al. 1994; Azad et al. 2011; Kelsey et al. 2010; Morán et al. 2012; Xiang et al. 
2012).  Additionally, carnosic acid is an anti-inflammatory (Kuo et al. 2011) and epicatechin 
monogallate displays some chemopreventive (Du et al. 2012) and antimicrobial properties 
(Hamilton-Miller & Shah 2000).  Similarly, gossypetin was among the powerful inhibitors and 
also is noted to be both anti-inflammatory (Trendafilova et al. 2011) and an antioxidant 
(Mounnissamy et al. 2002).  Each of these compounds warrants further animal research, and 
should availability permit, growth performance studies could reveal more as to their potential 
use.  However, two particular compounds stood out as potent inhibitors with definite novel 
potential as feed additives that could replace AGP: riboflavin and phenethyl caffeate (CAPE).  
Riboflavin, or vitamin B2, plays a key role in energy metabolism and is a conenzyme in 
numerous redox reactions (Combs 2012).  Aside from contributions to animal physiology, it is 
water-soluble and causes no known toxicities from supplementation at upper limits (National 
Academic Press 1987), although even at the lowest concentrations tested, riboflavin was still an 
extremely potent BSH inhibitor.  Because it is an FDA-approved feed additive with well-
established metabolic function and would be readily available to incorporate into feed, riboflavin 
likely may be an acceptable candidate to improve growth performance for food animals.  CAPE, 
on the other hand, is an emerging plant bioactive studied because it has antioxidant (Altuğ et al. 
2008; Lee (b) et al. 2008; Dos Santos & Monte-Alto-Costa 2013), anticarcinogenic (Chung et al. 
2004; Chan et al. 2012;), anti-inflammatory (da Cunha et al. 2004; Yilmaz et al. 2005; Dos 
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Santos & Monte-Alto-Costa 2013), immunomodulatory (Chan et al. 2012;), and antimicrobial 
(Yilmaz et al. 2005) effects.   It is a phenolic component of propolis and can be directly extracted 
or artificially synthesized by several methods (Akyol et al. 2012).  Although much research has 
been done to characterize the aforementioned effects of CAPE, no published data exist 
concerning its effects on growth performance of food animals.  Because CAPE can inhibit BSH 
at low concentrations (0.625 mM), a trial of this natural product as a feed supplement would 
certainly be highly warranted.  
This initial 2,240 compound screen was undoubtedly a step in the right direction towards 
identifying AGP replacements.  The HTS protocol may have some limitations, but nevertheless 
proved that it could successfully identify compounds that were potent BSH inhibitors.  Future 
chemical screens will be performed on libraries of over 50,000 small molecule candidates which 
may reveal more novel BSH inhibitors.  Having a greater number of applicable compounds will 
allow us to choose those with the most redeemable qualities that would include animal and 
environmental safety, cost, and availability.  A comparison of BSH inhibitors (riboflavin and 
CAPE) versus AGP will be useful for assessing performance improvements relative to the cost of 
supplementation.  Likely it will be challenging to compete with the low price of AGP 
supplementation.  One study reported that the cost of AGP ranged from $1.25 to $3.00 per ton of 
feed, and for chickens specifically the cost of AGP per bird was $0.0093 (Graham et al. 2007).  
However, despite that low price, the authors noted that the improved production performance 
was still not enough to offset the cost of AGP use.  Potent BSH inhibitors, therefore, may be able 
to compensate for price via larger improvements to animal health and performance.  Based on 
the in vitro data, it is estimated that riboflavin and CAPE could be delivered in the feed at 10 
mg/kg and 20 mg/kg, respectively, to exert efficient inhibition of BSH activity.  This is 
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comparable to AGP dosages that range from one up to 100 mg/kg in the feed depending on 
compound and animal type (van den Bogaard & Stobberingh 1999).  Particularly, riboflavin, a 
very potent BSH inhibitor, is a widely available product and if purchased in bulk, may come 
closer to approaching the cost of AGP supplementation.  Future HTS screens could also reveal 
BSH inhibitors that are broadly recognized compounds that would be especially cost effective.  
Furthermore, consumers may be willing to pay slightly more for products coming from animals 
reared without the use of AGP, which is stigmatized in today’s market.  
The long term goal of this study is, of course, to undertake a large-scale animal study 
using poultry as our model to test some of these novel inhibitors, including riboflavin and CAPE. 
While in vitro studies are absolutely useful for gathering preliminary data, intestinal in vivo 
conditions are certainly more complex.  Particularly, to be an effective inhibitor of intracellular 
BSH enzymes, our chemical compounds would need to traverse the cell envelope effectively by 
a means comparable to many clinical antibiotics.  Additionally, in vivo stability and 
bioavailability must be addressed in order to establish the validity and practicality of utilizing 
such inhibitors as a legitimate alternative to AGP.  Moreover, growth performance parameters 
like body weight gain, feed intake, and feed conversion ratio will need to be measured as well as 
morphological characteristics of the intestinal tract and meat and carcass quality.  This will help 
to rule out or identify any negative physiological consequences associated with prolonged use of 
a particular BSH inhibitor.  For example, because the BSH inhibitors should improve lipid 
metabolism, it is important to determine that energy harvest and weight gain is partitioned 
adequately and not skewed toward excess fat deposition, which would be undesirable for 
consumers.  If potent inhibitors are identified which do result in improved performance and 
carcass characteristics, it may also be beneficial to do an additional study assessing the sensory 
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evaluation of meat to ensure that there is no negative effect on meat flavor, odor, or tenderness.  
It is hoped that subsequent studies will be able to address the above concerns and corroborate the 
performance-boosting benefits of novel BSH inhibitors.    
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Table 1. Activity of rBSH for different bile salts. 
 
a 
The following bile salts were used to determine the hydrolysis activity of rBSH: 
glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), glycocholic acid 
(GCA), taurochenodeoxycholic acid (TCDCA), taurodeoxycholic acid (TDCA), and taurocholic 
acid (TCA)  
  
Substrate
a 
BSH activity (µmol/min/mg) Relative activity (%) 
GCDCA 
GDCA 
GCA 
TCDCA 
TDCA 
TCA 
17.7 ± 1.18 
4.0 ± 0.54 
7.7 ± 0.48 
8.0 ± 2.37 
8.5 ± 2.26 
5.6 ± 0.33 
100 
22.3 
41.9 
45.1 
47.9 
31.4 
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Table 2. Effect of different compounds on rBSH activity.
a
 
 
Compound % Inhibition 
CuCl2 98.1 
KIO3 96.5 
NaIO4 96.4 
FeSO4 96.1 
CoCl2 95.9 
Na2SeO3 93.1 
Retinol 93.1 
CuSO4 91.7 
Linolenic acid 90.1 
ZnSO4 89.5 
NaIO3 86.4 
Linoleic acid 84.7 
MnSO4 83.1 
CaCl2 22.4 
FeCl3 73.0 
ZnCl2 68.3 
MnCl2 68.1 
KI 36.8 
Cholecalciferol 36.0 
Sodium acetate 32.7 
NaI 31.8 
Sodium proprionate 31.4 
MgSO4 31.3 
Sodium butyrate 29.0 
NaSO4 27.7 
NaCl 27.7 
KCl 25.9 
MgCl2 25.7 
CaCl2 22.4 
Ascorbic acid 21.8 
NaHCO3 20.6 
Sodium lactate 15.4 
α-tocopherol -1.0 
Stearic acid -9.4 
Citric acid -38.9 
a 
The final concentration of all compounds in the reaction mix is 5 mM. 
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Table 3. The ten promising hits of BSH inhibitors discovered from HTS using a small compound 
library (2,240 compounds from Spectrum). 
 
 
 
  
Compound 
Name 
Structure Formula 
(MW) 
Source      Features References 
Epicatechin 
monogallate 
 
C22H18O10 
(442.38) 
Tea pigment antioxidant; 
chemopreventive;  
Du et al. 2012; 
Hamilton-Miller et al. 
2000; Terao et al. 
1994 
Carnosic acid 
 
C20H28O4 
(332.44) 
Salvia spp, 
Rosmarinus 
officinalis 
Potent antioxidant; 
anti-inflammatory; 
neuroprotective 
Morán et al. 2012; 
Xiang et al. 2012; 
Azad et al.  2011; 
Kuo et al.  2011 
Theaflavanin 
 
C20H16O8 
(384.34) 
Semi-
synthetic 
analog of 
theaflavin 
Anti-inflammatory; 
antiviral and 
antibacterial  
Zu et al. 2012; Betts 
et al. 2011; Aneja et 
al. 2011 
Chrysophanol 
 
C15H10O4 
(254.24) 
Cassia and 
Rumex spp. 
Anti-inflammatory; 
anticarcinogenic; 
anti-diabetic 
properties 
Lee et al. 2011; Kim 
et al.  2010; Lee et al.  
2008 
 
 
Phenethyl 
caffeate 
(CAPE) 
 
C17H16O4 
(284.31) 
Natural 
component 
of propolis 
from 
honeybee 
hives 
Antioxidant; 
anticarcinogenic; 
anti-inflammatory; 
immuno-
modulatory; 
antimicrobial 
Chan et al.  2012; 
Altuğ et al.  2008; 
Lee(b) et al.  2008; 
Yilmaz et al.  2005; 
Chung et al.  2004; da 
Cunha et al.  2004 
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Table 3. Continued 
 
Compound 
Name 
Structure Formula 
(MW) 
Source Features References 
Gossypetin 
 
C15H10O8 
(318.24) 
Widespread 
in plants 
Antioxidant; anti-
inflammatory 
Trendafilova et al.  
2011; Mounnissamy 
et al.  2002 
 
Purpurogallin 
 
C11H8O5 
(220.18) 
Gall of 
Dryophanta 
divisa 
Antioxidant; anti-
inflammatory; 
hepatoprotective; 
cardioprotective; 
antibacterial 
activity 
Kim (b) et al.  2012; 
Inamori et al. 1997; 
Wu et al. 1996; 
Prasad et al. 1994; 
Wu et al. 1994; Wu et 
al. 1991 
 
Folic acid 
 
C19H19N7O6 
(441.40) 
Liver, 
kidney, 
green plants 
and fungi 
Vitamin used for 
nucleotide 
biosynthesis; upper 
limits considered 
nontoxic; no 
environmental risks 
associated with use 
in animal nutrition 
EFSA 2012; National 
Academic Press 1987 
 
Riboflavin 
 
C17H20N4O6 
(376.37) 
Retina, 
whey and 
urine 
Vitamin that has a 
role in energy 
metabolism; 
coenzyme in 
numerous redox 
reactions; upper 
limits considered 
nontoxic 
Combs & Gerald 
2012; National 
Academic Press 1987 
Menadione 
 
C11H8O2 
(172.18) 
Asplenium 
and Juglans 
spp. 
Vitamin important 
in process of blood 
clotting and calcium 
metabolism; used as 
a nutritional 
supplement in 
chicken and turkey 
feed; can be added 
as high as 1000 
times the dietary 
requirement without 
resulting in adverse 
effects 
FDA 2012; Pillai et 
al.  2008 
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Table 4. Validation of the selected BSH inhibitors determined by HTS.
*
 
 
 
Compound % Inhibition 
CAPE 96.4  
Carnosic Acid 96.8 
Chrysophanol
a 
3.7  
Epicatechin monogallate 98.6 
Folic Acid
b 
-10.8 
Gossypetin 97.3 
Menadione 87.2 
Purpurogallin 83.0 
Riboflavin
c 
94.5 
Theaflavanin 18.1 
 
* 
Unless specified, the final concentration of compound in the reaction mix was 5mM. 
a
The final  concentration of chrysophanol in reaction mix was  1.25 mM. 
b
The final  concentration of folic acid in reaction mix was 1.5 mM. 
c 
The final  concentration of riboflavin in reaction mix was 1 mM. 
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Figure 1.  Production and purification of rBSH (SDS-PAGE analysis). Lane 1 is a prestained 
molecular marker.  Lane 2 is whole-cell lysate of noninduced E. coli, followed by whole-cell 
lysate of E. coli induced with 0.5 mM IPTG after 1 hr (Lane 3), 1.5 hrs (Lane 4), 2 hrs (Lane 5), 
2.5 hrs (Lane 6), and 3 hrs (Lane 7).  Lane 8 is rBSH purified by Ni-NTA affinity 
chromatography.  
kDa 
 
66 
 
 
 
45 
 
 
 
 
25 
 
 
18 
  1             2            3             4            5             6             7            8 
rBSH 
(37 kDa) 
64 
 
 
 
 
 
 
Figure 2.  SDS-PAGE analysis of stepwise purification of the rBSH.  Lane 1, a prestained 
molecular marker; lane 2, induced whole-cell lysate of E. coli; lane 3, flow-through fraction; lane 
4, wash fraction.  Lanes 5-10 indicate eluents 1 through 6, respectively.  
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Figure 3. The effect of pH on rBSH activity.  rBSH activity was measured in 0.1 M sodium 
citrate-citrate acid buffer for pH values ranging from 3.0 to 5.4 and in 0.1 M sodium phosphate 
buffer for pH values ranging from 6.0 to 8.0. Each bar represents the mean BSH activity ± 
standard deviation at each pH tested. 
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Figure 4. The effect of temperature on rBSH activity.  rBSH activity was measured over a range 
of temperatures (20°C-75°C) in 0.1 M sodium phosphate buffer (pH 6.0).  Each bar represents 
the mean BSH activity ± standard deviation of each temperature.  
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Figure 5.  Validation of microplate method for screening BSH inhibitors using HTS.  A panel of 
iodine compounds were used to validate the microplate precipitation-based assay using a 200 µl 
of total reaction volume. All compounds were added at a final concentration of 0.5 mM in 
column 1 with 2-fold serial dilution through column 10.  Rows A and B: NaIO4; C and D: NaI; E 
and F: NaIO3; G and H: KI.  A 12.5 µl volume of BSH (50-fold diluted from a stock 
concentration of 8 μg/μl) was added in column wells 1-11.  Column 12 served as a negative 
control with no enzyme and compound added.    
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Figure 6.  Microplate precipitation-based assay for four dietary compounds that display potent 
inhibitory effect on BSH using the standard BSH assay.  Using 200 µl of total reaction volume, 
all compounds were added at a final concentration of 0.5 mM in column 1 with 2-fold serial 
dilution through column 10.  Rows A and B: CuCl2; C and D: ZnSO4; E and F: KIO3; G and H: 
Na2SeO3.  A 12.5 µl volume of BSH (50-fold diluted from a stock concentration of 8 μg/μl) was 
added in column wells 1-11.  Column 12 served as a negative control with no enzyme and 
compound added.    
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Figure 7. Validation of HTS protocol for screening BSH inhibitors.  (A) Design of validation 
plate:  blue boxes are activity controls (BSH, reaction mix containing substrate, and solvent 
DMSO) and yellow boxes are inhibition controls (BSH, reaction mix containing substrate, and 
NaIO3). (B) Results of the validation assay indicate that DMSO had no adverse effects on BSH 
activity (cloudy wells with precipitate) when compared to the wells containing a known inhibitor 
NaIO3 (clear wells).   
A 
B 
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Figure 8. Representative result of one plate from HTS of BSH inhibitors.  (A) Plate layout for 
HTS inhibitor screening.  Pink boxes indicate test wells that contain a library compound of 
interest, BSH, and reaction mix containing substrate.  Library compounds were shot into the well 
bottom using Echo 550/555 and enzyme and reaction mix were added using Multidrop Combi.  
Controls were added manually to the side wells:  blue boxes indicate activity controls (BSH, 
reaction mix containing substrate, and solvent DMSO), yellow boxes correspond to inhibition 
controls (BSH, reaction mix containing substrate, and NaIO3), and white boxes are negative 
controls with no BSH added but include reaction mix with substrate and DMSO. (B) The HTS 
results represented by one 384-well plate.  Control wells indicate the assay proceeded normally.  
The wells in columns 3-22 that appeared clear, regardless of alternative color due to compound, 
and had low absorbance readings were considered hits (putative BSH inhibitors).  
A 
B 
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Figure 9. Validation of four rBSH inhibitors identified by HTS using the 96-well plate assay. 
Using 50 µl of total reaction volume, all compounds were added at a final concentration of 0.5 
mM in column 1 with 2-fold serial dilution through column 10.  Rows A and B: carnosic acid; C 
and D: menadione; E and F: gossypetin; G and H: riboflavin.  BSH was added  at a fixed 
concentration in column wells 1-11.  Column 12 served as a negative control with no enzyme 
and compound added.  After 4 hours of incubation, gossypetin and riboflavin display the greatest 
inhibition, through well 8.  Menadione and carnosic acid inhibited activity at the three and five 
highest concentrations tested, respectively. 
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